A review of safety and efficacy of zonisamide for treatment of pediatric partial epilepsy

Maria Stella Vari, Pasquale Striano Paediatric Neurology and Muscular Diseases Unit, Department of Neurosciences, Rehabilitation, Ophtalmology, Genetics, Maternal and Child Health, University of Genoa, "G Gaslini" Institute, Genova, Italy Introduction: Zonisamide is one of the mo...

Full description

Bibliographic Details
Main Authors: Vari MS, Striano P
Format: Article
Language:English
Published: Dove Medical Press 2014-11-01
Series:Pediatric Health, Medicine and Therapeutics
Online Access:http://www.dovepress.com/a-review-of-safety-and-efficacy-of-zonisamide-for-treatment-of-pediatr-peer-reviewed-article-PHMT
id doaj-a439720842364f5394d5a2d4570947c8
record_format Article
spelling doaj-a439720842364f5394d5a2d4570947c82020-11-25T01:24:00ZengDove Medical PressPediatric Health, Medicine and Therapeutics1179-99272014-11-012014default15516019173A review of safety and efficacy of zonisamide for treatment of pediatric partial epilepsyVari MSStriano P Maria Stella Vari, Pasquale Striano Paediatric Neurology and Muscular Diseases Unit, Department of Neurosciences, Rehabilitation, Ophtalmology, Genetics, Maternal and Child Health, University of Genoa, "G Gaslini" Institute, Genova, Italy Introduction: Zonisamide is one of the most promising antiepileptic drugs that was first approved in Europe as add-on therapy in adult patients with partial seizures and recently approved as monotherapy. More recently, zonisamide has been approved for pediatric use in the UK and can now be prescribed for partial epilepsy in adolescents and children aged 6 years and above. Aim: This paper systematically reviews the current evidence on the efficacy and tolerability of zonisamide as monotherapy and adjunctive therapy for pediatric partial epilepsy. Methods: Relevant randomized clinical trials and open-label studies were identified by a structured PubMed search, supplemented by an additional hand search of reference lists and authors' files. Results: PubMed database search yielded 12 (four double-blind randomized, eight open-label) clinical trials published over the last 10 years (January 2004 to September 2014) and the pooled analysis included a total of 1,555 patients treated with zonisamide. Conclusion: Zonisamide currently represents a robust option in the treatment of children with partial epilepsy, based on its multiple mechanism of action and efficacy in different situations. Keywords: children, clinical trial, partial seizures, tolerabilityhttp://www.dovepress.com/a-review-of-safety-and-efficacy-of-zonisamide-for-treatment-of-pediatr-peer-reviewed-article-PHMT
collection DOAJ
language English
format Article
sources DOAJ
author Vari MS
Striano P
spellingShingle Vari MS
Striano P
A review of safety and efficacy of zonisamide for treatment of pediatric partial epilepsy
Pediatric Health, Medicine and Therapeutics
author_facet Vari MS
Striano P
author_sort Vari MS
title A review of safety and efficacy of zonisamide for treatment of pediatric partial epilepsy
title_short A review of safety and efficacy of zonisamide for treatment of pediatric partial epilepsy
title_full A review of safety and efficacy of zonisamide for treatment of pediatric partial epilepsy
title_fullStr A review of safety and efficacy of zonisamide for treatment of pediatric partial epilepsy
title_full_unstemmed A review of safety and efficacy of zonisamide for treatment of pediatric partial epilepsy
title_sort review of safety and efficacy of zonisamide for treatment of pediatric partial epilepsy
publisher Dove Medical Press
series Pediatric Health, Medicine and Therapeutics
issn 1179-9927
publishDate 2014-11-01
description Maria Stella Vari, Pasquale Striano Paediatric Neurology and Muscular Diseases Unit, Department of Neurosciences, Rehabilitation, Ophtalmology, Genetics, Maternal and Child Health, University of Genoa, "G Gaslini" Institute, Genova, Italy Introduction: Zonisamide is one of the most promising antiepileptic drugs that was first approved in Europe as add-on therapy in adult patients with partial seizures and recently approved as monotherapy. More recently, zonisamide has been approved for pediatric use in the UK and can now be prescribed for partial epilepsy in adolescents and children aged 6 years and above. Aim: This paper systematically reviews the current evidence on the efficacy and tolerability of zonisamide as monotherapy and adjunctive therapy for pediatric partial epilepsy. Methods: Relevant randomized clinical trials and open-label studies were identified by a structured PubMed search, supplemented by an additional hand search of reference lists and authors' files. Results: PubMed database search yielded 12 (four double-blind randomized, eight open-label) clinical trials published over the last 10 years (January 2004 to September 2014) and the pooled analysis included a total of 1,555 patients treated with zonisamide. Conclusion: Zonisamide currently represents a robust option in the treatment of children with partial epilepsy, based on its multiple mechanism of action and efficacy in different situations. Keywords: children, clinical trial, partial seizures, tolerability
url http://www.dovepress.com/a-review-of-safety-and-efficacy-of-zonisamide-for-treatment-of-pediatr-peer-reviewed-article-PHMT
work_keys_str_mv AT varims areviewofsafetyandefficacyofzonisamidefortreatmentofpediatricpartialepilepsy
AT strianop areviewofsafetyandefficacyofzonisamidefortreatmentofpediatricpartialepilepsy
AT varims reviewofsafetyandefficacyofzonisamidefortreatmentofpediatricpartialepilepsy
AT strianop reviewofsafetyandefficacyofzonisamidefortreatmentofpediatricpartialepilepsy
_version_ 1725119530332585984